Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of diabetes among related and unrelated family members

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Exercise training is associated with reduced pains from the musculoskeletal system in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: We have previously found that acute intravenous infusion of an ACE inhibitor normalized the reduced coronary vasomotor function in type 2 diabetes. The aim of the present study was to extend this investigation to an angiotensin II receptor blocker (ARB) administered orally in normotensive, asymptomatic type 2 diabetes patients without albuminuria.

RESULTS: Fourteen type 2 diabetes patients were included. Each patient had myocardial perfusion measured by PET at three occasions: at baseline, following 3 weeks of treatment with 50mg/d and following another 3 weeks of treatment with 100mg/d of losartan. Baseline myocardial perfusion was similar at all three sessions (0.89+/-0.05, 0.90+/-0.08 and 0.84+/-0.05mL/(ming) tissue, respectively). Likewise, maximal hyperaemic perfusion after i.v. dipyridamole (0.56mg/kg bwt) was low but similar at the three sessions (2.01+/-0.14, 2.05+/-0.17 and 1.90+/-0.20mL/(ming) tissue, respectively). Myocardial perfusion reserve, i.e. maximal hyperaemic flow relative to baseline flow, was also low, but similar before and after treatment with losartan (2.36+/-0.24, 2.44+/-0.24 and 2.62+/-0.42mL/(ming) tissue, respectively).

CONCLUSIONS: Oral treatment with an ARB did not normalize coronary vasomotor function in type 2 diabetes patients without cardiovascular disease.

Original languageEnglish
JournalDiabetes Research and Clinical Practice
Volume84
Issue number1
Pages (from-to)34-8
Number of pages5
ISSN0168-8227
DOIs
Publication statusPublished - Apr 2009

    Research areas

  • Adult, Aged, Angiotensin II Type 1 Receptor Blockers, Blood Pressure, Coronary Circulation, Diabetes Mellitus, Type 2, Electrocardiography, Female, Heart Rate, Hemodynamics, Humans, Losartan, Male, Middle Aged, Positron-Emission Tomography, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't

ID: 50128997